263 related articles for article (PubMed ID: 37988953)
21. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
22. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
23. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
[TBL] [Abstract][Full Text] [Related]
24. Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group's Comparative Survey Study.
Cho WK; Yoo GS; Rim CH; Jeong JU; Chie EK; Ahn YC; Cho HM; Um JW; Suh YG; Chang AR; Lee JH;
Cancer Res Treat; 2023 Oct; 55(4):1281-1290. PubMed ID: 37290481
[TBL] [Abstract][Full Text] [Related]
25. Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Wu Y; Verma V; Liang F; Lin Q; Zhou Z; Wang Z; Wang Y; Wang J; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):635-644. PubMed ID: 35196537
[TBL] [Abstract][Full Text] [Related]
26. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma.
Webking S; Sandoval ML; Chuong MD; Ucar A; Aparo S; De Zarraga F; Sahin I; Biachi T; Kim DW; Hoffe SE; Frakes JM; Palm RF
Cancer Control; 2023; 30():10732748231219069. PubMed ID: 38038261
[TBL] [Abstract][Full Text] [Related]
27. Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review.
Giaj-Levra N; Giaj-Levra M; Durieux V; Novello S; Besse B; Hasan B; Hendriks LE; Levy A; Dingemans AC; Berghmans T;
J Thorac Oncol; 2019 Dec; 14(12):2053-2061. PubMed ID: 31195177
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study.
Kroese TE; Jorritsma NKN; van Laarhoven HWM; Verhoeven RHA; Mook S; Haj Mohammad N; Ruurda JP; van Rossum PSN; van Hillegersberg R
Clin Transl Radiat Oncol; 2022 Nov; 37():109-115. PubMed ID: 36186924
[TBL] [Abstract][Full Text] [Related]
29. Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer.
Kroese TE; Buijs GS; Burger MDL; Ruurda JP; Mook S; Brosens LAA; van Rossum PSN; van Hillegersberg R
Ann Surg Oncol; 2022 Aug; 29(8):4848-4857. PubMed ID: 35381938
[TBL] [Abstract][Full Text] [Related]
30. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection.
Yang J; Zhang J; Lui W; Huo Y; Fu X; Yang M; Hua R; Wang L; Sun Y
HPB (Oxford); 2020 Jan; 22(1):91-101. PubMed ID: 31262486
[TBL] [Abstract][Full Text] [Related]
31. Resection of isolated liver oligometastatic disease in pancreatic ductal adenocarcinoma: Is there a survival benefit? A systematic review.
Halle-Smith JM; Powell-Brett S; Roberts K; Chatzizacharias NA
World J Gastrointest Surg; 2023 Jul; 15(7):1512-1521. PubMed ID: 37555114
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract][Full Text] [Related]
33. Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.
Ottaiano A; De Luca A; Santorsola M; Scognamiglio G; Di Mauro A; Chiodini P; Lambiase M; Sacco A; Petrillo A; Granata V; Fusco R; Mercadante E; Martucci N; De Luca G; Rocca A; Celentano E; Crispo A; Di Gennaro P; Tatangelo F; Ferrara G; Izzo F; Belli A; Patrone R; Delrio P; Rega D; De Franciscis S; Muto P; Ravo V; Di Franco R; Borzillo V; Santagata S; Rea G; Castaldo D; Pace U; De Feo G; Scala S; Nasti G; Normanno N
BMC Cancer; 2023 Oct; 23(1):1010. PubMed ID: 37858132
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
35. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
36. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
37. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
[TBL] [Abstract][Full Text] [Related]
38. Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.
Chen Y; Wang Y; Yang Z; Hu M; Lu J; Zhang Y; Qian F; Zhang B; Wang S; Wang K; Zhang W; Han B
Thorac Cancer; 2022 Mar; 13(5):732-741. PubMed ID: 35060346
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).
Wei M; Shi S; Hua J; Xu J; Yu X;
BMJ Open; 2019 Dec; 9(12):e033452. PubMed ID: 31818843
[TBL] [Abstract][Full Text] [Related]
40. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Frost N; Roeper J; Velthaus JL; Raspe M; Olive E; Schmittel A; Schmidt B; Wasilewski D; Onken J; Lüders H; Witzenrath M; Senger C; Böhmer D; Loges S; Griesinger F; Modest DP; Grohé C
Lung Cancer; 2022 Aug; 170():165-175. PubMed ID: 35803041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
